

16944 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

are decreasing in frequency. A high percentage of these deaths have been determined to be suicides by medical examiners and coroners. The laboratory data on many of the deaths classified as accidental indicate blood and tissue concentrations of propoxyphene and other drugs far in excess of those that could be expected from use of such drugs at recommended doses.

Propoxyphene has not been associated with significant "street abuse" and its dependence liability is limited.

Lilly does not believe that propoxyphene products should be placed in Schedule II of the Controlled Substances Act. Nevertheless, the company will continue to cooperate with the Food and Drug Administration, the Drug Enforcement Administration, and this committee in their further evaluation of propoxyphene.

#

Darvocet^R (propoxyphene hydrochloride and acetaminophen, Lilly)
Darvon^R (propoxyphene hydrochloride, Lilly)
Darvon-N^R (propoxyphene napsylate, Lilly)